Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioItaLEE molecular profiling study of ribociclib + letrozole in HR-positive/HER2-negative advanced breast cancer
2017-004176-62Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ribociclib and letrozole in breast cancer, sponsored by Novartis. Primary endpoint: ctDNA alterations over time and association with clinical outcomes. Started Jan 2021; status: terminated.
02
Drugs
ribociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-004176-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004176-62.